A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.

Autor: Berenson JR; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA. jberenson@berensoncancercenter.com.; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA. jberenson@berensoncancercenter.com.; Berenson Cancer Center, West Hollywood, CA, USA. jberenson@berensoncancercenter.com., Limon A; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Rice S; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Safaie T; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD, USA., Yang H; The Oncology Institute of Hope and Innovation, Alhambra, CA, USA., Moezi M; Cancer Specialists of North Florida, Fleming Island, FL, USA., Lim S; Cedars Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA., Schwartz G; Berenson Cancer Center, West Hollywood, CA, USA., Eshaghian S; Los Angeles Cancer Network, Los Angeles, CA, USA., Brobeck M; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Swift R; Berenson Cancer Center, West Hollywood, CA, USA., Eades BM; Berenson Cancer Center, West Hollywood, CA, USA., Bujarski S; Berenson Cancer Center, West Hollywood, CA, USA., Sebhat Y; Berenson Cancer Center, West Hollywood, CA, USA., Ray R; Berenson Cancer Center, West Hollywood, CA, USA., Kim S; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Del Dosso A; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Vescio R; Cedars Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.

Publikováno v: Targeted oncology [Target Oncol] 2024 May; Vol. 19 (3), pp. 343-357. Date of Electronic Publication: 2024 Apr 20.

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.

Autor: Berenson JR; Berenson Cancer Center, West Hollywood, Los Angeles, California, USA.; Oncotherapeutics, West Hollywood, Los Angeles, California, USA.; Institute for Myeloma and Bone Cancer Research, West Hollywood, Los Angeles, California, USA., Kim C; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Bujarski S; Berenson Cancer Center, West Hollywood, Los Angeles, California, USA., To J; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Spektor TM; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Martinez D; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Turner C; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Ghermezi M; Oncotherapeutics, West Hollywood, Los Angeles, California, USA., Eades BM; Berenson Cancer Center, West Hollywood, Los Angeles, California, USA., Swift RA; Berenson Cancer Center, West Hollywood, Los Angeles, California, USA., Schwartz G; Berenson Cancer Center, West Hollywood, Los Angeles, California, USA., Eshaghian S; Compassionate Care Research Group, Fountain Valley, Los Angeles, California, USA., Moss RA; F.A.C.P., Inc, Fountain Valley, Los Angeles, California, USA., Lim S; Cedars-Sinai Medical Center, Los Angeles, California, USA., Vescio R; Cedars-Sinai Medical Center, Los Angeles, California, USA.

Publikováno v: Hematological oncology [Hematol Oncol] 2022 Dec; Vol. 40 (5), pp. 906-913. Date of Electronic Publication: 2022 Aug 14.

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.

Autor: Daniely D; Institute for Myeloma & Bone Cancer Research, Los Angeles, CA., Forouzan E; Oncotherapeutics, Los Angeles, CA., Spektor TM; Oncotherapeutics, Los Angeles, CA., Cohen A; Oncotherapeutics, Los Angeles, CA., Bitran JD; Oncology Specialists SC, Park Ridge, IL., Chen G; John Muir Medical Center, Walnut Creek, CA., Moezi MM; Cancer Specialists of North Florida, Fleming Island, FL., Bessudo A; California Cancer Associates for Research & Excellence (cCARE), Encinitas, CA., Hrom J; Hattiesburg Clinic of Hematology and Oncology, Hattiesburg, MS., Eshaghian S; Compassionate Oncology Medical Group, Los Angeles, CA., Swift RA; James R. Berenson, MD, Inc., Los Angeles, CA., Eades BM; James R. Berenson, MD, Inc., Los Angeles, CA., Kim C; Oncotherapeutics, Los Angeles, CA., Lim S; Cedars-Sinai Cancer Center, West Hollywood, CA., Berenson JR; Institute for Myeloma & Bone Cancer Research, Los Angeles, CA; Oncotherapeutics, Los Angeles, CA; James R. Berenson, MD, Inc., Los Angeles, CA. Electronic address: jberenson@berensoncancercenter.com.

Publikováno v: Experimental hematology [Exp Hematol] 2022 Jul; Vol. 111, pp. 79-86. Date of Electronic Publication: 2022 Apr 10.

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.

Autor: Berenson JR; James R. Berenson, MD, Inc., West Hollywood, California. jberenson@imbcr.org.; Oncotherapeutics, West Hollywood, California.; Institute for Myeloma and Bone Cancer Research, West Hollywood, California., To J; Oncotherapeutics, West Hollywood, California., Spektor TM; Oncotherapeutics, West Hollywood, California., Martinez D; Oncotherapeutics, West Hollywood, California., Turner C; Oncotherapeutics, West Hollywood, California., Sanchez A; Oncotherapeutics, West Hollywood, California., Ghermezi M; Oncotherapeutics, West Hollywood, California., Eades BM; James R. Berenson, MD, Inc., West Hollywood, California., Swift RA; James R. Berenson, MD, Inc., West Hollywood, California., Schwartz G; James R. Berenson, MD, Inc., West Hollywood, California., Eshaghian S; James R. Berenson, MD, Inc., West Hollywood, California., Stampleman L; Pacific Cancer Care, Monterey, California., Moss RA; Robert A. Moss, MD., F.A.C.P., Inc, Fountain Valley, California., Lim S; Cedars-Sinai Medical Center, Los Angeles, California., Vescio R; Cedars-Sinai Medical Center, Los Angeles, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 May 15; Vol. 26 (10), pp. 2346-2353. Date of Electronic Publication: 2020 Jan 14.